Glaucoma Research Foundation receives $1.6 million gift

Article

The Glaucoma Research Foundation has received the largest single gift in its 32 year history. The staggering $1.6 million gift from the Melza M. and Frank Theodore Barr Foundation and is to support the ongoing research of the Catalyst For a Cure consortium to discover a cure for glaucoma.

The Glaucoma Research Foundation has received the largest single gift in its 32 year history. The staggering $1.6 million gift from the Melza M. and Frank Theodore Barr Foundation and is to support the ongoing research of the Catalyst For a Cure consortium to discover a cure for glaucoma. “The Barrs have been very generous in their support of glaucoma research and their gift will have a major impact on the effort to find new treatments and eventually a cure for glaucoma,” said Thomas Brunner, president and CEO of Glaucoma Research Foundation.

The Catalyst For a Cure research consortium is in its ninth year and takes a unique approach to glaucoma research. Unlike conventional research, which often operates in isolation until results can be published, the Catalyst For a Cure was formed with the goal of real time collaboration to speed the process of discovery. Four principal scientists at four universities brought their experience in neuroscience, genetics, molecular biology and vision to curing glaucoma, the second leading cause of blindness worldwide. Together the team has accelerated the pace of discovery and brought new understanding to vision loss from glaucoma. The principal scientists include Monica Vetter, PhD, University of Utah, Nick Marsh-Armstrong, PhD, Johns Hopkins University, Phil Horner, PhD, University of Washington, and David Calkins, PhD, Vanderbilt University.

Read more about the work of CFC.

www.glaucoma.org

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.